Skip to main content

Table 3 Safety and efficacy analysis of HIV and HBV/HCV cohorts

From: Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection

Cohorts (N)

ORRa

N (%)

Any Grade irAEs

N (%)

Grade ≥ 3 irAEs

N (%)

HIV (21)

2 CR/3 PR (28)

5 (24)

3 (14)

HBV/HCV (34)

6 PR (18)

15 (44)

10 (29)b

  1. aResponse evaluable patients HIV: 18; HBV/HCV: 34, b Two patients with baseline grade ≥ 2 hepatitis